Navigation Links
Study Shows Pine Bark Naturally Reduces Osteoarthritis
Date:4/16/2008

reated patients.

Patients were allowed to use their regular dosage of NSAIDS. Usage dropped by 58 percent during treatment with Pycnogenol(R) and one percent with the placebo. Evaluation of data demonstrated a decrease of gastrointestinal complications of 64 percent in the Pycnogenol(R) group versus three percent in placebo.

"The results of this study are significant as they clearly demonstrate the clinical action of Pycnogenol(R) on OA and management of symptoms. The use of Pycnogenol(R) many reduce costs and side effects of anti-inflammatory agents and offer a natural alternative solution to people suffering from OA," said Dr. Belcaro.

A previous study on osteoarthritis which was carried out at the University of Arizona Tucson (published in Nutrition Research) had discovered that Pycnogenol(R) was effective for improving pain and joint function. After three months in the Pycnogenol(R) group, there was a reduction of 43 percent in pain, 35 percent in stiffness, 52 percent in physical function subscales, respectively. The placebo group showed no significant scores throughout the entire study. Dr. Belcaro confirms this earlier study with a much larger number of patients and with a more detailed investigation procedure.

The benefits of Pycnogenol(R) for arthritic joints are suggested to result predominantly from the anti-inflammatory potency of Pycnogenol(R) which was demonstrated in a series of clinical investigations in the past. There are more breakthrough studies on Pycnogenol(R) and osteoarthritis expected to be published next year allowing for development of innovative, natural formulas for joint health. Additionally, Horphag Research, the exclusive worldwide distributor of Pycnogenol(R) has filed for several patents for Pycnogenol's(R) application for COX-1, COX-2 and treating osteoarthritis.

"The new research in the field of osteoarthritis has been a paradigm shift for Pycnogenol(R). We were able to demonstrate Pycnogenol's(R
'/>"/>

SOURCE Natural Health Science Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Study suggests too much screen time and not enough physical activity may lead to childhood obesity
2. St. Jude gene study reveals basis of anticancer drug resistance in childhood leukemia
3. UAB study shows investigational drug may treat biliary cancers
4. Study shows that high-dose, high-frequency interferon produces no additional benefit
5. Study finds media coverage of breast cancer focuses too little on prevention
6. USC study finds evidence of gender-related differences in development of colon cancer
7. New study in JCSM finds that obesity can predict upper airway obstruction amongst children
8. Study shows increase of hip and knee replacements in the US
9. Study shows decline in work disability due to rheumatoid arthritis
10. Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients
11. Study sheds light on deadly lung disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...,s Bed & Back; Merger Sets Up Healthy Back as...ain, LORTON, Va., May 16 /PRNewswire/ -- Healthy ...and workplace back wellness created an,ergonomic r...its rival,JoAnne,s Bed & Back. Healthy Back,s 18 ...s of $40million. JoAnne,s 16 mid-Atlantic stores,c...
(Date:5/16/2008)...wire-USNewswire/ -- This release is,being sent in ...on with the,National Cancer Institute, part of the...he American Society of Clinical,Oncology meeting i...ractice,in about 25 percent of patients with colon...he way colorectal cancers will be staged., * This...
(Date:5/16/2008)...s gain benefit from calcitriol, an oral form , ... activated vitamin D may cut the risk of death for...ease by about one quarter, a new study suggests. ...tients, those being treated with calcitriol, an or...risk of death lowered by 26 percent when compared ...
(Date:5/16/2008)...aise $38 Million for Life-threatening,Disease, BE...kers in nearly,every state will raise funds for cy...participating in GREAT STRIDES, the largest nation...announced today., May is National Cystic Fibrosis...ening genetic disease that causes fatal lung infec...
Breaking Medicine News(10 mins):Health News:The Back Wars Come to a Close 2Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2
... assistants, typically graduate students hired to ... college campuses. Indiana University shyness expe...eople hired to help new students with their conver...become staples, as well. New students, said Cardu...
...trial body recognizing the downward trend of acces...wo things needed to reverse the situation- more mo... According to the Federation of Indian Chambers ...dia needs to spend around $203 billion (Rs 912,37...
...traditional diet of fish, tofu, vegetables and ric...r, but a change of eating habits is weighing down...ry estimates that every second male and every fift...and experts have identified a change in lifestyle ...
...udy has found that what boys lose in the process o...parts of the penis. The long-term-health impact ...y, while the consequences of circumcision on sexua... male have received even less attention. But now,...
Other Medicine News:Health News:Binge Drinking on College Campuses is a Matter of Fear, Not Freedom 2Health News:Binge Drinking on College Campuses is a Matter of Fear, Not Freedom 3Health News:FICCI Proposes Models To Solve Indias Healthcare Crisis 2Health News:Japanese are Weighed Down by Deviating from Their Traditional Diet 2
(Date:5/16/2008)...wswire-FirstCall/ -- Pulmo BioTech Inc. (OTC,Bulle...ethodology and,purpose of its Phase I Human Trials...or the diagnosis of Pulmonary Embolism and Pulmona... the Pulmo BioTech subsidiary,PulmoScience Inc., ...e Use,of PulmoBind for Molecular Imaging of the Pu...
(Date:5/16/2008).../- BioVex Inc, a biotechnology,compan...nd infectious,disease, announced today that the ab...se II clinical trial of OncoVEX GM-CSF in advanced...can Society of Clinical Oncology,(ASCO) website lo...bstract,which describes the data as of the submiss...
(Date:5/16/2008).../- Veridex, LLC announced today that,... of America Holdings,(LabCorp), has commercially l...ancer. The new assay uses the biological specifici...ing the methylation of the gene,GST-Pi. Methylatio...n,cancer. Veridex is developing the methylation ma...
(Date:5/15/2008)...May 15 /- Eisai Corporation of North,...cal data abstracts about,compounds in the company,...ical oncology research have been accepted for pres...n Society of Clinical Oncology (ASCO),taking plac... variety of abstracts on Eisai marketed products a...
Breaking Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Sea otter study reveals striking variability in diets and feeding strategies 1893 1Sea otter study reveals striking variability in diets and feeding strategies 1893 2Sea otter study reveals striking variability in diets and feeding strategies 1893 3Three Rivers Pharmaceuticals 28R 29 LLC Acquires Hepatitis C Drug Infergen 28R 29 from Valeant Pharmaceuticals 9529 1Three Rivers Pharmaceuticals 28R 29 LLC Acquires Hepatitis C Drug Infergen 28R 29 from Valeant Pharmaceuticals 9529 2Huron Capital Caps Strong Year With Five Acquisitions In 4Q07 9527 1Huron Capital Caps Strong Year With Five Acquisitions In 4Q07 9527 2Huron Capital Caps Strong Year With Five Acquisitions In 4Q07 9527 3Sickle Cell Disease Pain Can Occur Daily and Is Much More Severe Than Previously Thought 9525 1Sickle Cell Disease Pain Can Occur Daily and Is Much More Severe Than Previously Thought 9525 2
...., June 26, 2007 /PRNewswire-FirstCall/ -- Microme...the development of,novel, proprietary antibody-bas...e diseases, announced that a study published recen...Sciences (1) supports,the findings of several othe... target for Micromet,s product candidates adecatum...
...(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corporation,... in the,development and commercialization of human... the six-month, open-label extension,of its comple...LS,volunteers. While the clinical trial was not pl...ee times daily appeared to be safe,and well-tolera...
Other Medicine Technology:Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers 2Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers 3Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers 4CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 2CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 3CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 4CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 5
...reg; PLUS Biomaterial is the first hernia repair m...ing potential operative contamination of the mater...antimicrobial preservative agents, silver carbonat...t bacterial colonization on the patch for up to 10...
...the Bard Kugel Patch, which is constructed of a do...o layers create a positioning pocket, which is use...the other side is a barrier of ePTFE. The patch al...," which causes the patch to spring open and maint...
...eshaped Mesh is constructed of Bard polypropylene ...40 years. Developed with the world renowned Lichte...sh takes the guesswork out of sizing and shaping t...inal hernia repair procedure.,Its three-dimension...
...mesh is a three-dimensional, anatomically formed p...he Bard 3DMax mesh has been designed based on care...l canal. The result is a truly unique prosthesis f...oduct is constructed of Bard mesh, knitted polypro...
Medicine Products: